1-(3,4-Dichlorophenyl)-2-pyridin-4-yl-ethane-1,2-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,4-Dichlorophenyl)-2-pyridin-4-yl-ethane-1,2-dione
• 英文别名: 1-(3,4-Dichlorophenyl)-2-pyridin-4-yl-ethane-1.2-dione；1-(3,4-dichlorophenyl)-2-pyridin-4-ylethane-1,2-dione
• 化学式: C₁₃H₇Cl₂NO₂
• 分子量: 280.11
• InChiKey: AHGPTUYZWFVVDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3,4-Dichlorophenyl)-2-pyridin-4-yl-ethane-1,2-dione 、 4-甲酰基-N-CBZ 哌啶 在 ammonium acetate 、 溶剂黄146 、 Ammonium hydroxide 作用下， 以 水 为溶剂， 反应 2.5h， 生成 4-[5-(3,4-dichlorophenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]piperidine-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY

  摘要：

  公开号：

  EP0854870B1
• 作为产物：
  描述：

  1-(3,4-dichlorophenyl)-2-pyridin-4-yl-ethane-1,2-diol 在 二甲基亚砜 、 三氟乙酸酐 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.34h， 生成 1-(3,4-Dichlorophenyl)-2-pyridin-4-yl-ethane-1,2-dione
  参考文献：
  名称：

  SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY

  摘要：

  公开号：

  EP0854870B1

文献信息

• Combination therapy
  申请人：——

  公开号：US20040102360A1

  公开（公告）日：2004-05-27

  The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.

  本发明涉及使用至少两种Akt抑制剂的组合或一种同时是Akt抑制剂和蛋白激酶抑制剂的化合物来治疗癌症的方法，该方法包括向哺乳动物施用来自以下组合中选择的至少两种治疗剂的量，该组合包括Akt抑制剂和蛋白激酶抑制剂。该发明还涉及制备这种组合物的方法。
• Method of treating cancer
  申请人：Barnett F Stanley

  公开号：US20060142178A1

  公开（公告）日：2006-06-29

  The present invention is directed to a method of treating cancer which comprises administration of a compound which selectively inhibits the activity of one or two of the isoforms of Akt, a serine/threonine protein kinase. The invention is particularly directed to the method wherein the compound is dependent on the presence of the pleckstrin homology domain of Akt for its inhibitory activity.

  本发明涉及一种治疗癌症的方法，包括给予一种选择性抑制丝氨酸/苏氨酸蛋白激酶Akt中的一种或两种异构体活性的化合物。本发明特别涉及该方法中，该化合物依赖于Akt的pleckstrin同源结构域存在以发挥其抑制活性。
• Imidazol-2-carboxamide derivatives as raf kinase inhibitors
  申请人：——

  公开号：US20030134837A1

  公开（公告）日：2003-07-17

  Compounds of the formula (I) wherein X is O, CH 2 , S or NH, or the moiety X—R 1 is hydrogen; V is CH or N; R 1 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heterocyclyl, hererocyclylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl any of which except hydrogen may be optionally substituted; R 2 and R 3 independently represent hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heteroaryl, heteroarylC 1-6 alkyl, heterocyclyl, or heterocyclylC 1-6 alkyl any one of which except hydrogen may be optionally substituted, or R 2 and R 3 together with the nitrogen atom to which they are attached form a 4- to 10-membered optionally substituted monocyclic or bicyclic ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X 1 and X 2 is N and the other is NR 4 , wherein R 4 is hydrogen, C 1-6 alkyl, or arylC 1-6 alkyl; or pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them.

  化合物的公式（I），其中X为O，CH2，S或NH，或者X-R1基团为氢；V为CH或N；R1为氢，C1-6烷基，C3-7环烷基，芳基，芳基C1-6烷基，杂环基，杂环基C1-6烷基，杂芳基或杂芳基C1-6烷基，其中除氢外任何一种均可选择性地被取代；R2和R3独立地表示氢，C1-6烷基，C3-7环烷基，芳基，芳基C1-6烷基，杂芳基，杂芳基C1-6烷基，杂环基或杂环基C1-6烷基，其中除氢外任何一种均可选择性地被取代，或者R2和R3与它们所附着的氮原子一起形成一个4-至10-成员的可选择性取代的单环或双环环；Ar为芳基或杂芳基环，其中任何一个都可以选择性地被取代；X1和X2中的一个为N，另一个为NR4，其中R4为氢，C1-6烷基或芳基C1-6烷基；或其药学上可接受的盐；它们作为Raf激酶抑制剂的用途和含有它们的制药组合物。
• Imidazol derivatives as Raf kinase inhibitors
  申请人：SmithKline Beecham p.l.c.

  公开号：US07235658B2

  公开（公告）日：2007-06-26

  Compounds of formula (I): wherein X is O, CH2, S or NH, or the moiety X—R1 is hydrogen; V is CH or N; R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heterocyclyl, heterocyclylC1-6alkyl, heteroaryl, or heteroarylC1-6alkyl any of which except for hydrogen may be optionally substituted; R2 and R3 independently represent optionally substituted C1-6alkyl, or R2 and R3 together with the carbon atom to which they are attached form an optionally substituted C3-7cycloalkyl or C3-7cycloalkenyl ring; or R2 and R3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.R4 and R5 independently represent hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heteroaryl, heteroarylC1-6alkyl, heterocyclyl, or heterocyclylC1-6alkyl, any of which except for hydrogen may be optionally substituted or R4 and R5 together with the nitrogen atom to which they are attached form 4- to 8-membered ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X1 and X2 is N and the other is NR6, wherein R6 is hydrogen, C1-6alkyl, or arylC1-6alkyl or pharmaceutically acceptable salts thereof, their use as inhibitors of Raf kinases, and pharmaceutical compositions containing them.

  化合物的式子（I）： 其中， X为O，CH2，S或NH，或者X-R1是氢； V为CH或N； R1为氢，C1-6烷基，C3-7环烷基，芳基，芳基C1-6烷基，杂环基，杂环基C1-6烷基，杂芳基或杂芳基C1-6烷基，除氢外任何一种都可以选择性地被取代； R2和R3独立地表示选择性取代的C1-6烷基，或者R2和R3与它们所附着的碳原子一起形成一个选择性取代的C3-7环烷基或C3-7环烯基环；或者R2和R3与它们所附着的碳原子一起形成一个选择性取代的5到7成员的杂环烷基环，其中含有最多3个从N，O，S中选择的杂原子。 R4和R5独立地表示氢，C1-6烷基，C3-7环烷基，芳基，芳基C1-6烷基，杂芳基，杂芳基C1-6烷基，杂环基或杂环基C1-6烷基，除氢外任何一种都可以选择性地被取代，或者R4和R5与它们所附着的氮原子一起形成4到8成员的环； Ar是芳基或杂芳基环，任意一种都可以选择性地被取代； X1和X2中的一个是N，另一个是NR6，其中R6是氢，C1-6烷基或芳基C1-6烷基； 或其药学上可接受的盐，它们用作Raf激酶的抑制剂，以及含有它们的制药组合物。
• US6083949
  申请人：——

  公开号：——

  公开（公告）日：——